JNJ stock forecast, quote, news & analysis

Key Takeaways

• JNJ shares surged approximately 10.8% over the past 30 days, climbing from $228.39 on June 18 to $253.04 as of July 17, 2026, driven by strong Q2 earnings and raised full-year guidance.
• The company reported Q2 2026 adjusted EPS of $2.90 on revenue of $25.31 billion, beating Wall Street consensus estimates, while raising its full-year revenue midpoint to $101.1 billion — the first $100-billion year in its 140-year history.
• Innovative Medicine led the charge with 7.8% reported sales growth, powered by blockbusters DARZALEX, TREMFYA (up 72.5%), CARVYKTI, and new launches ICOTYDE and INLEXZO.
• MedTech revenue grew 4.5% but fell slightly short of analyst expectations, with Abiomed softness offsetting strength in Surgery, Vision, and Orthopedics.
• Analyst sentiment turned decisively bullish, with multiple firms raising price targets into the $260–$305 range following the earnings beat and guidance hike.

Johnson & Johnson (JNJ) Company Overview and Market Position

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, operating across two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). With 28 platforms generating more than $1 billion in annual sales, the company maintains leading positions in oncology, immunology, neuroscience, cardiovascular care, surgery, vision, and orthopedics. Founded in 1886 and headquartered in New Brunswick, New Jersey, JNJ is a Dividend King with over six decades of consecutive annual dividend increases. Its AAA-rated balance sheet, roughly $21 billion in free cash flow generation, and broad commercial portfolio make it a cornerstone holding for institutional investors and a benchmark for the large-cap healthcare sector. The company's strategic pivot toward higher-growth oncology and immunology franchises, combined with the planned separation of its Orthopaedics business, has refocused the investment narrative around accelerating revenue growth and pipeline-driven value creation.

Johnson & Johnson (JNJ) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 calendar days, JNJ posted a gain of roughly 10.8%, rising from a closing price of $228.39 on June 18, 2026, to $253.04 on July 17, 2026. The rally accelerated in late June and early July, sending shares to a 52-week high of $269.43 on July 7, before a post-earnings pullback trimmed some of those gains. Over the broader quarter, the stock has climbed from levels near $240 in mid-April to current prices above $250, reflecting sustained upward momentum. Year-to-date, JNJ has appreciated approximately 22.1%, significantly outperforming the broader large-cap pharmaceutical industry, which has gained roughly 10.2% over the same period. The stock trades above both its 50-day moving average of approximately $239.82 and its 200-day moving average of $234.63, confirming a bullish technical structure.

What Drove JNJ Stock Price in the Last 30 Days

The primary catalyst behind JNJ's 10.8% surge was the company's second-quarter 2026 earnings release on July 15, which surpassed Wall Street expectations on both revenue and earnings. Johnson & Johnson reported adjusted EPS of $2.90, beating the consensus estimate of $2.84, while revenue of $25.31 billion exceeded forecasts of $25.18 billion. More importantly, management raised its full-year 2026 guidance, projecting reported sales of $100.8 billion to $101.4 billion with a midpoint of $101.1 billion, and adjusted EPS of $11.60 to $11.75 with a midpoint of $11.68. The $100-billion revenue milestone represents a historic first for the company.

Innovative Medicine was the standout performer, with sales rising 7.8% to $16.38 billion. TREMFYA more than delivered, surging 72.5% to $2.0 billion on strong inflammatory bowel disease uptake. Oncology products DARZALEX, CARVYKTI, TECVAYLI, and RYBREVANT/LAZCLUZE all posted robust double-digit growth. New launches ICOTYDE and INLEXZO also contributed meaningfully, with ICOTYDE reaching over 10,000 patient starts within its first months. Notably, excluding STELARA biosimilar headwinds, underlying Innovative Medicine growth was in the double digits.

The rally was further supported by a wave of analyst upgrades and price target increases. Scotiabank set a $305 target, TD Cowen raised its target to $300, Morgan Stanley lifted to $294, and Goldman Sachs reiterated its Buy rating at $282. Institutional accumulation also provided a tailwind, with more than 69% of shares held by institutional investors. The stock's pre-earnings climb toward $269 also reflected broad rotation into defensive healthcare names and anticipation of a strong quarterly print.

What Drove JNJ Stock Performance Over the Last Quarter

The broader quarterly rally in JNJ reflects a multi-month narrative shift from litigation and patent-cliff concerns toward pipeline execution and accelerating growth. Throughout the second quarter, investors steadily re-rated the stock as the company delivered a series of positive clinical data readouts, regulatory approvals, and strategic milestones. FDA approvals for TREMFYA's psoriatic arthritis label expansion, CAPLYTA for schizophrenia relapse prevention, and the Dual Energy THERMOCOOL SMARTTOUCH SF ablation platform reinforced confidence in the innovation pipeline. Positive Phase 3 data for ERLEADA in prostate cancer and multiple pipeline advances across oncology and immunology further validated the growth thesis. The planned DePuy Synthes Orthopaedics separation, which analysts view as a multiple-unlocking catalyst, added another layer of strategic clarity. Meanwhile, the company's strong Q1 results, reported in April, set a positive tone that carried into the Q2 earnings beat, cementing the view that JNJ has successfully navigated past its most significant patent headwinds and is entering a period of sustained above-market revenue growth.

Trending AI Robots

For investors seeking data-driven approaches to navigate stocks like Johnson & Johnson, Tickeron's Trending AI Robots page offers a curated view into the platform's most relevant and top-performing automated trading strategies. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of tickers across different timeframes and market conditions, but the Trending section highlights only those robots demonstrating consistent performance metrics and alignment with current market dynamics. These bots vary widely in their strategic approach — from short-term momentum and swing trading to longer-duration trend-following models — giving traders the flexibility to match automated strategies with their own risk tolerance and investment objectives. Exploring the Trending AI Robots page can help traders identify AI-driven insights and tools designed to complement their own research.

JNJ Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several key factors will shape JNJ's trajectory. The pace of ICOTYDE and INLEXZO commercial uptake will be closely scrutinized, as these new launches are central to the company's post-STELARA growth story. In MedTech, recovery in Abiomed procedure volumes and the OTTAVA robotic surgery platform's regulatory progress represent critical catalysts. The planned DePuy Synthes Orthopaedics separation carries execution risk but could unlock shareholder value if completed on schedule. Upcoming clinical data readouts — including the milvexian atrial fibrillation trial results potentially late in 2026 — could materially impact sentiment. On the risk side, ongoing talc litigation remains a persistent financial overhang, and competitive pressure in pulsed field ablation weighs on the electrophysiology business. Additionally, Medicare drug price negotiation outcomes and macroeconomic factors affecting hospital procedure volumes will influence both MedTech demand and pharmaceutical pricing. With consensus analyst estimates now clustering between $260 and $305, execution on the company's raised guidance will be the primary determinant of whether JNJ can sustain its recent momentum.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations